Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) for Diagnosis of TB Infection in Elderly
NCT05899179Phase 3Completed
- Sponsor
- Zhifei Biological
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant mycobacterium tuberculosis fusion protein (EC) in latent tuberculosis infection (LTBI) (2 arms), sponsored by Zhifei Biological. Primary endpoints: Diameter of redness or induration at the reaction site at 72 hours, Incidence of all adverse events at 7 days and 5 more. Started Aug 2023; status: completed.
02
Drugs
recombinant mycobacterium tuberculosis fusion protein (EC)
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT05899179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899179.